终末期肾病患者SARS-CoV-2感染后的中和抗体反应及再感染保护
该研究评估了164例终末期肾病(ESKD)患者的SARS-CoV-2血清阳性率及中和抗体功能,发现总体血清阳性率为36%,血液透析患者更高(44.2%),无症状者也可出现血清转换但部分无中和抗体;随访中位数93天后多数人仍可检测到中和抗体,但滴度显著下降,提示可能维持一定保护。
要点
- ESKD患者SARS-CoV-2血清阳性率36%,血透患者44.2%。
- 无症状感染者也可血清转换,但12例无中和抗体者均为无症状。
- 随访93天后多数仍可检测中和抗体,但滴度显著下降。
核心结论
- ESKD患者包括无症状者常发生血清转换并产生可检测的中和抗体,虽IgG随时间下降但多数中和抗体仍可检测,提示可能维持一定保护。
研究设计与样本
- 研究纳入截至2020年8月的164例ESKD患者,采集血清样本,采用ELISA检测SARS-CoV-2刺突S1亚基和核蛋白抗体,并用假病毒中和试验评估中和活性。
主要发现
- 17例RT-PCR确诊感染者中16例血清转换。
- 总体血清阳性率(抗S1和/或抗N IgG)为36%,血透患者为44.2%。
- 血清转换者中35.6%无症状;12例无中和抗体滴度者均为无症状。
- 基线后中位93天重复检测显示多数人保留可检测应答,但S1、N和中和抗体滴度显著下降。
临床怎么用
- ESKD患者无论有无症状均应考虑SARS-CoV-2血清学检测以评估免疫状态。
- 中和抗体随时间下降,需关注再感染风险,尤其初始应答较弱者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with end-stage kidney disease (ESKD) represent a vulnerable group with multiple risk factors that are associated with poor outcomes after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite established susceptibility to infectious complications and the importance of humoral immunity in protection against SARS-CoV-2, few studies have investigated the humoral immune response to SARS-CoV-2 within this population. Here, we evaluate the seroprevalence of SARS-CoV-2 in patients awaiting renal transplantation and determine whether seroconverted patients with ESKD have durable and functional neutralizing activity against SARS-CoV-2. METHODS: Serum samples were obtained from 164 patients with ESKD by August 2020. Humoral immune responses were evaluated by SARS-CoV-2 spike S1 subunit and nucleoprotein semiquantitative enzyme-linked immunosorbent assay (ELISA) and SARS-CoV-2 spike pseudotype neutralization assay. RESULTS: All patients with ESKD with reverse-transcriptase polymerase chain reaction (RT-PCR)-confirmed infection (n = 17) except for 1 individual seroconverted against SARS-CoV-2. Overall seroprevalence (anti-S1 and/or anti-N IgG) was 36% and was higher in patients on hemodialysis (44.2%). A total of 35.6% of individuals who seroconverted were asymptomatic. Seroconversion in the absence of a neutralizing antibody (nAb) titer was observed in 12 patients, all of whom were asymptomatic. Repeat measurements at a median of 93 days from baseline sampling revealed that most individuals retained detectable responses although a significant drop in S1, N and nAb titers was observed. CONCLUSION: Patients with ESKD, including those who develop asymptomatic disease, routinely seroconvert and produce detectable nAb titers against SARS-CoV-2. Although IgG levels wane over time, the neutralizing antibodies remain detectable in most patients, suggesting some level of protection is likely maintained, particularly in those who originally develop stronger responses.
引用
- Muir L, Jaffer A, Rees-Spear C, et al. Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection. Kidney Int Rep. 2021. PMID: 33942026. doi:10.1016/j.ekir.2021.03.902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。